COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD ZincZn
HC Q study #49
Source   Share   Tweet
See all 155 studies
Post Exposure Prophylaxis study (treated after exposure to the virus)
Boulware et al., NEJM, June 3 2020, doi:10.1056/NEJMoa2016638 (Peer Reviewed)
A Randomized Trial of Hydroxych loroquine as Postexposure Prophylaxis for Covid-19
COVID-19 cases are reduced by [49%, 29%, 16%] respectively when taken within ~[70, 94, 118] hours of exposure (including shipping delay). The treatment delay-response relationship is significant at p=0.002. PEP delayed treatment RCT.
Currently this is the only study where we have evaluated the result as positive while the authors indicate it is negative. We provide a detailed explanation of why the results presented here are positive [1]. Note that author comments also differ from the published conclusion.
6 independent analyses confirm efficacy: [2, 3, 4, 5, 6, 7, 8].
COVID-19 case, ↓17.0%, p=0.35
COVID-19 case, ↓25.1%, p=0.22, probable COVID-19 case
Source   Share   Tweet
See all 155 studies
Please send us corrections, updates, or comments.